Relmada Therapeutics Faces Setbacks in Depression Trials and Explores Strategic Alternatives

Relmada Therapeutics has decided to halt its RELIANCE II and Relight trials for REL-1017, a treatment intended for major depressive disorder, after a futility assessment by an independent Data Monitoring Committee indicated that the trials were unlikely to meet their primary efficacy endpoints[1][2]. These phase 3 trials had enrolled approximately 340 patients each and were part of Relmada's broader effort to establish REL-1017 as an effective adjunctive treatment for MDD[1]. The decision comes in the wake of previous failures with REL-1017, including the RELIANCE III trial, which failed to surpass the placebo effect[1].